LON:VRPVerona Pharma Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verona Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 41 0.00 (0.00 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range 37.40Now: GBX 41▼ 42.2550-Day Range 37MA: GBX 42.92▼ 6052-Week Range 28.60Now: GBX 41▼ 102Volume68,141 shsAverage Volume49,797 shsMarket Capitalization£43.55 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartHeadlinesOptions Chain Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Verona Pharma. Previous Next 2.4 Community Rank Outperform VotesVerona Pharma has received 227 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVerona Pharma has received 248 “underperform” votes. (Add your “underperform” vote.)Community SentimentVerona Pharma has received 52.21% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote “Outperform” if you believe VRP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:VRP Previous Symbol CUSIPN/A CIKN/A Webwww.veronapharma.com Phone+44-20-32834200Debt Debt-to-Equity Ratio5.55 Current Ratio3.91 Quick Ratio3.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 19.70 per share Price / Cash Flow2.08 Book ValueGBX 24.50 per share Price / Book1.67Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees22 Outstanding Shares106,214,000Market Cap£43.55 million Next Earnings DateN/A OptionableOptionable LSE:VRP Rates by TradingView Receive VRP News and Ratings via Email Sign-up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter. Verona Pharma (LON:VRP) Frequently Asked Questions How has Verona Pharma's stock been impacted by COVID-19 (Coronavirus)? Verona Pharma's stock was trading at GBX 49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRP shares have decreased by 16.3% and is now trading at GBX 41. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Verona Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Verona Pharma. How were Verona Pharma's earnings last quarter? Verona Pharma Plc (LON:VRP) released its quarterly earnings results on Thursday, February, 27th. The company reported ($30.30) EPS for the quarter, beating the consensus estimate of ($30.80) by $0.50. View Verona Pharma's earnings history. Has Verona Pharma been receiving favorable news coverage? Media coverage about VRP stock has trended very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verona Pharma earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutVerona Pharma. Who are some of Verona Pharma's key competitors? Some companies that are related to Verona Pharma include Resverlogix (RVX), Neuren Pharmaceuticals (NEU), Faron Pharmaceuticals Oy (FARN), Helix Biopharma (HBP), Horizon Discovery Group (HZD), OncoCyte (OCX), Tiziana Life Sciences (TILS), Orgenesis (ORGS), Oncolytics Biotech (ONC), Monash IVF Group (MVF), Burcon NutraScience (BU), BioTime (BTX), Lineage Cell Therapeutics (LCTX), Matinas BioPharma (MTNB) and Imugene (IMU). View all competitors. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include VERONA PHARMA P/S (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), GRIFOLS S A/S (GRFS) and Innoviva (INVA). Who are Verona Pharma's key executives? Verona Pharma's management team includes the following people: Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)Mr. Piers John Morgan, Chief Financial Officer (Age 53)Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)Ms. Victoria Stewart, Director of CommunicationsDr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57) What is Verona Pharma's stock symbol? Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP." How do I buy shares of Verona Pharma? Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Verona Pharma's stock price today? One share of VRP stock can currently be purchased for approximately GBX 41. How big of a company is Verona Pharma? Verona Pharma has a market capitalization of £43.55 million. Verona Pharma employs 22 workers across the globe. What is Verona Pharma's official website? The official website for Verona Pharma is www.veronapharma.com. How can I contact Verona Pharma? Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200. This page was last updated on 5/25/2020 by MarketBeat.com Staff
